Six peptides, two legal lives: the HHS enforcement-discretion notice

On October 28, 2026, the Department of Health and Human Services filed a notice for the Federal Register announcing an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It publishes on October 30 under docket HHS-OASH-2026-0496 and RIN 0910-ZD94, with two weeks for comment after the fact. Its operative sentence is one line long: HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A. Appendix A, as reported by every outlet that has seen it, lists six peptides: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax.

By the Associated Press's account the same day, the policy was written over the objections of most of the FDA's scientific staff, who had limited input in drafting it. This piece sets out what was filed, how it got here, what it does and does not change, and the questions it leaves open, in particular for anyone who buys or sells these six molecules as research materials. Those six have reference entries in this library: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax.

What was filed

The document is a notice of availability, three pages, signed by the Secretary. It describes itself as a draft, says the policy applies while the list of bulk drug substances that can be used in compounding under section 503A of the FD&C Act (the 503A bulks list) is developed through rulemaking, and gives its reason in one sentence: based on the Pharmacy Compounding Advisory Committee meetings and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved products. It adds that HHS may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises, and that the policy does not establish any rights for any person and is not binding on HHS or the public.

The conditions sit in the policy document itself, hosted on hhs.gov rather than in the notice. As reported by the AP and NBC News on October 28, pharmacies are to source the bulk peptide from FDA-registered facilities, verify its chemical identity, and collect information on adverse events for safety analysis. Those were, by the AP's account, guardrails that FDA staff asked for once it was clear the policy would issue regardless.

How it got here

• 2023. FDA places BPC-157, TB-500 and more than a dozen other peptides in Category 2 of its interim bulks-list policy: substances that raise significant safety concerns and are not to be compounded.
• April 15–16, 2026. FDA announces it will remove twelve peptides from Category 2 and publishes a Federal Register notice (FR Doc. 2026-07361, docket FDA-2025-N-6895) convening a re-formed Pharmacy Compounding Advisory Committee to consider seven of them for the 503A bulks list. Removal from Category 2 does not authorize compounding; only placement on the list, by rule, does.
• July 23–24, 2026. The committee votes. BPC-157, KPV and TB-500 pass 8–6 with one abstention; MOTS-c 7–5 with two; semax and epitalon by similar margins; emideltide (DSIP) is rejected. The FDA briefing documents prepared by career staff had recommended against every one. For BPC-157 the conclusion reads: a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed on that list, because the substance is considered not well-characterized from the physical and chemical characterization perspective, with naming that does not follow established chemical nomenclature standards and data on critical quality attributes for establishing its identity, purity, and quality that were either lacking or deemed to be inadequate. The roster, published by FDA, shows a committee on which several voting members work at clinics or companies that offer peptides.
• October 14, 2026. HHS sends an Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94, to the White House Office of Information and Regulatory Affairs for review. Its text is not public.
• October 16, 2026. The Partnership for Safe Medicines petitions FDA not to allow compounding of the six, calling them untested and poorly defined.
• October 21, 2026. OIRA holds an Executive Order 12866 meeting on the policy at the request of the American Academy of Peptide Medicine, the record of which is public.
• October 27, 2026. OIRA concludes its review, consistent with change: the document changed while under review.
• October 28, 2026. The notice is filed, now titled an enforcement discretion policy rather than an access policy; the AP reports the staff opposition and that HHS, not FDA, drove it.

What it is, and what it is not

It is worth being exact, because the headlines are not. The policy is not a rule: no proposal, no comment period before it takes effect, no finding. It is not an approval: HHS's own summary says compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness, or quality before they are marketed. It does not put anything on the 503A bulks list; the notice says in terms that FDA's future rulemakings may propose adding some or all of these peptides. It binds nobody, including HHS, and it can be narrowed or withdrawn on a safety signal without any process at all.

What it is, is a statement by the department that it will not use its enforcement power against a defined class of people doing a defined thing. That is a real thing with real effects: a pharmacy that reads it will compound, and a state board that reads it will have to decide whether to follow it. But it is enforcement discretion, and enforcement discretion is a choice about whom to pursue, not a determination about a molecule.

Two points should be conceded plainly. The Secretary has the authority: the drug provisions of the Act are the Secretary's, delegated to FDA, and a delegation can be exercised from above. And the demand is real: the notice's reason, significant interest and lack of availability of approved products, is true as a description of the market.

The questions it leaves open

Policy by enforcement choice, in both directions

This library has argued that FDA's reading of intended use is made by enforcement letter rather than by rule: a conclusion published in a warning, with no notice, no comment and no court. The same architecture now runs the other way. A Secretary who disagrees with the agency's reviewers does not have to overrule their finding; he can announce that it will not be enforced. In both directions the public gets a decision without a process, and in both directions the decision can change on a signal. A supplier planning a year ahead, a pharmacy planning a formulary, a laboratory planning a program: none of them has anything to rely on but the department's present mood.

Demand is not evidence

The notice's rationale is about interest and availability. The briefing documents' objection was about characterization: the substances are not well enough defined, chemically, to know what a pharmacy would be compounding. Those are different questions, and the policy answers the first while leaving the second where the reviewers found it. Identity, purity and the quality attributes that fix them do not change because a notice says compounding may proceed. They are exactly what a certificate of analysis is supposed to settle, lot by lot, and exactly what the briefing documents found wanting in the nominations.

The same molecule, two legal lives

From October 30, a vial of BPC-157 made by a bulk manufacturer and compounded by a pharmacy against a prescription is a product the department has said it will leave alone. The same molecule, from the same bulk manufacturer, in a vial labeled for laboratory research and sold on a website that also offers a solvent and a calculator, is an unapproved new drug in FDA's eyes: that is precisely the evidence the agency's August 24, 2026 warning letters cite (references 733652, 734884, 735127, 735063 and 735067 on the enforcement tracker). Two weeks before the notice, a group of senators asked FDA to work with Customs and Border Protection against sellers who, in their words, misuse research labeling to sell unapproved drugs. Nothing in the new policy touches research-labeled products; the department's lawyers were careful about that. The effect is to sharpen the line, not to move it. A regulated channel now exists for these six, which makes the unregulated channel easier to describe as the problem.

For the research market the lesson is the one this library has drawn before: the label is read against everything around it. A research supplier of these six molecules is in the same legal position on October 31 as on October 27, provided the rest of the site supports the label. The difference is that the comparison is now explicit, and the supplier whose page looks like a pharmacy without the pharmacy's obligations will find that comparison made for them. What research use only means and the mistakes that undo it set out where the line has been drawn in the letters.

Who answers when something goes wrong

A policy that can be withdrawn on a safety signal needs signals. The reported conditions ask pharmacies to collect adverse-event information, and that is a real improvement on a market that had none. But the policy is explicitly not binding, the collection is a condition of discretion rather than a duty under a rule, and the committee that recommended these substances had, by FDA's own roster, members with an interest in the answer. When the first signal comes, the question of who decided, on what evidence, will be asked, and the record will show a notice of availability signed by the Secretary.

What to watch

• October 30: publication, and the start of a two-week docket at regulations.gov (HHS-OASH-2026-0496). The comments will show who supports this and who intends to challenge it.
• The policy text and Appendix A as finally posted on hhs.gov: which conditions survived OIRA's change, and how identity verification and adverse-event collection are defined.
• Whether FDA proposes the rule the notice says it may: a proposed addition to the 503A bulks list would, for the first time, put the reviewers' findings and the committee's votes through notice and comment.
• State boards of pharmacy, which the policy does not bind, and the first state to say so.
• The petition of October 16, and whether its authors go to court.
• Enforcement on the other side of the line: the next warning letters and the next civil suits over research-labeled products, which this policy has made easier to bring.

Frequently asked questions

Does the October 28 policy make BPC-157 or the other five peptides legal?

No. It says HHS does not intend to enforce against licensed pharmacies, federal facilities and physicians compounding them under section 503A. It is not an approval, not a rule, and not a placement on the bulks list; the notice says it binds nobody and can be revisited on a safety signal.

Does it change anything for research-labeled peptides?

Not in law. The policy is confined to 503A compounding. In practice it sharpens the contrast between a compounded product with a prescription and a research-labeled product sold with a solvent and a calculator, which the FDA's August 2026 letters count as evidence of intended use.

What did FDA's own reviewers say?

The briefing documents for the July 2026 advisory committee recommended against each of the seven nominated peptides. For BPC-157 the reviewers found the substance not well characterized, with inadequate data on the attributes that establish identity, purity and quality.

Can the public comment?

Yes, for two weeks from October 30, 2026, on docket HHS-OASH-2026-0496 at regulations.gov. The comment period follows the policy rather than preceding it.

Which peptides are covered?

As reported from Appendix A: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Emideltide (DSIP), the seventh substance considered in July, was not recommended and is not included.

Sources & Further Reading

1. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, RIN 0910-ZD94; filed October 28, 2026, publication October 30, 2026. Public-inspection PDF at public-inspection.federalregister.gov/2026-22192.pdf. Policy document at hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf.
2. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. 91 FR 20465, April 16, 2026, FR Doc. 2026-07361, Docket FDA-2025-N-6895.
3. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: FDA briefing document for BPC-157-related bulk drug substances (fda.gov/media/193343/download), section III, "Conclusion and Recommendation"; final meeting roster (fda.gov/media/193772/download).
4. Office of Information and Regulatory Affairs. RIN 0910-ZD94, Interim Access Policy for Compounding Using Certain Peptides: received October 14, 2026; EO 12866 meeting of October 21, 2026 (requestor: American Academy of Peptide Medicine); concluded October 27, 2026, consistent with change. reginfo.gov.
5. Partnership for Safe Medicines. Citizen petition to FDA regarding compounding of six peptides, filed October 16, 2026; announcement of October 26, 2026.
6. Perrone M. FDA scientists opposed the Trump administration's effort to ease peptides access. Associated Press, October 28, 2026.
7. NBC News. RFK Jr. takes shortcut to make some unapproved peptides available for use. October 28, 2026.
8. United States Senate, Office of Senator Jim Banks. Banks urges FDA to crack down on illicit "research use only" drugs. Press release, October 2026.
9. FDA warning letters of August 24, 2026 to online sellers of research-labeled peptides, references 733652, 734884, 735127, 735063, 735067: enforcement tracker.

Cosmic Peptides. (2026, October 28). Six peptides, two legal lives: the HHS enforcement-discretion notice. Cosmic Peptides Research Library. Retrieved October 29, 2026, from https://cosmicpeptides.com/research/perspectives/six-peptides-two-legal-lives

@misc{cosmicpeptides_research_perspectives_six_peptides_two_legal_lives,
  author       = {{Cosmic Peptides}},
  title        = {Six peptides, two legal lives: the HHS enforcement-discretion notice},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = oct,
  url          = {https://cosmicpeptides.com/research/perspectives/six-peptides-two-legal-lives},
  urldate      = {2026-10-29},
  note         = {Last reviewed 2026-10-28}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Six peptides, two legal lives: the HHS enforcement-discretion notice
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/10/28
UR  - https://cosmicpeptides.com/research/perspectives/six-peptides-two-legal-lives
Y2  - 2026/10/29
LA  - en
ER  -